Xeris Biopharma Holdings Inc XERS:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/16/24 EDT
2.04quote price arrow up+0.02 (+0.99%)
Volume
19,830
Close
2.02UNCH (UNCH)
Volume
1,383,265
52 week range
1.46 - 3.26
Loading...
  • Open1.98
  • Day High2.07
  • Day Low1.93
  • Prev Close2.02
  • 52 Week High3.26
  • 52 Week High Date02/15/24
  • 52 Week Low1.46
  • 52 Week Low Date11/15/23

Key Stats

  • Market Cap299.477M
  • Shares Out148.26M
  • 10 Day Average Volume1.49M
  • Dividend-
  • Dividend Yield-
  • Beta1.78
  • YTD % Change-14.04

KEY STATS

  • Open1.98
  • Day High2.07
  • Day Low1.93
  • Prev Close2.02
  • 52 Week High3.26
  • 52 Week High Date02/15/24
  • 52 Week Low1.46
  • 52 Week Low Date11/15/23
  • Market Cap299.477M
  • Shares Out148.26M
  • 10 Day Average Volume1.49M
  • Dividend-
  • Dividend Yield-
  • Beta1.78
  • YTD % Change-14.04

RATIOS/PROFITABILITY

  • EPS (TTM)-0.46
  • P/E (TTM)-4.35
  • Fwd P/E (NTM)-5.04
  • EBITDA (TTM)-32.609M
  • ROE (TTM)-617.16%
  • Revenue (TTM)171.356M
  • Gross Margin (TTM)82.90%
  • Net Margin (TTM)-37.58%
  • Debt To Equity (MRQ)-2,502.44%

EVENTS

  • Earnings Date08/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Xeris Biopharma Holdings Inc

 

Profile

MORE
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an...
Paul Edick
Chairman of the Board, Chief Executive Officer
John Shannon
President, Chief Operating Officer
Steven Pieper
Chief Financial Officer
Address
1375 West Fulton Street, Suite 1300
Chicago, IL
60607
United States

Top Peers

SYMBOLLASTCHG%CHG
AKBA
Akebia Therapeutics Inc
1.14UNCHUNCH
AGEN
Agenus Inc
10.50UNCHUNCH
STRO
Sutro Biopharma Inc
4.15UNCHUNCH
FGEN
FibroGen Inc
1.24UNCHUNCH
TRDA
Entrada Therapeutics Inc
14.95UNCHUNCH